Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling

British Journal of Cancer

Volumn 90, Issue 9, 2004, Pages 1814-1824

  Santin, A D ^a,d   Zhan, F ^b   Bellone, S ^a   Palmieri, M ^a   Cane, S ^a   Gokden, M ^b   Roman, J J ^a   O'Brien, T J ^a   Tian, E ^b   Cannon, M J ^b   Shaughnessy Jr , J ^b   Pecorelli, S ^c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

Author keywords

Gene expression profiling; Her 2 neu; Herceptin; Serous papillary ovarian cancer; Serous papillary uterine cancer

Indexed keywords

ADULT; AGED; ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; FEMALE; FLOW CYTOMETRY; GENE CLUSTER; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC MARKER; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARIAN SEROUS PAPILLARY CANCER; OVARY CANCER; PAPILLARY CARCINOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; UTERINE CERVIX CANCER; UTERINE SEROUS PAPILLARY CARCINOMA;

ADULT; AGED; CARCINOMA, PAPILLARY; CELLS, CULTURED; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UTERINE NEOPLASMS;

EID: 2642573440     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601791     Document Type: Article

References (32)

1. Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activation system in tumour growth, invasion, and metastasis. Cell Mol Life Sci 57: 25-40
2. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P (1990) Overexpression of HER-2/ neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087-4091
3. Budnik LT, Mukhopadhyay AK (2002) Lysophosphatidic acid and its role in reproduction. Biol Reprod 66: 859-865
4. Carcangiu ML, Chambers JT (1992) Uterine papillary serous carcinoma: a study on 108 cases with emphasis on prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian cancer. Gynecol Oncol 47: 298-305
5. Carcangiu ML, Chambers JT (1995) Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium, comparison of clinicopathological features and survival. Int J Gynecol Pathol 14: 30-38
6. Chambers SK, Ivins CM, Carcangiu ML (1997) Expression of plasminogen activator inhibitor-2 in epithelial ovarian cancer: a favorable prognostic factor related to the actions of CSF-1. Int J Cancer 74: 571-575
7. Contos JJ, Ishii I, Chun J (2000) Lysophosphatidic acid receptors. Mol Pharmacol 58: 1188-1196
8. David G (1993) Integral membrane heparan sulfate proteoglycans. FASEB J 7: 1023-1030
9. Deligdisch L, Holinka CF (1987) Endometrial carcinoma: two diseases? Cancer Detect Prev 10: 237-246
10. Eisen MB, Spellman PT, Brown PO, Bostein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Aca Sci USA 95: 14863-14868
11. Giordano TJ, Shedden KA, Schwartz DR, Kuick R, Taylor JM, Lee N, Misek DE, Greenson JK, Kardia SL, Beer DG, Rennert G, Cho KR, Gruber SB, Fearon ER, Hanash S (2001) Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol 159: 1231-1238
12. Goff BA, Kato D, Schmidt RA, Ek M, Ferry JA, Muntz HG, Cain JM, Tamimi HK, Figge DC, Greer BE (1994) Uterine papillary serous carcinoma: pattern of metastatic spread. Gynecol Oncol 54: 264-268
13. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ (2001) Coordinately up-regulated genes in ovarian cancer. Cancer Res 61: 3869-3876
14. Ismail RS, Baldwin RL, Fang J, Browning D, Karlan BY, Gasson JC, Chang DD (2000) Differential gene expression between normal and tumour-derived ovarian epithelial cells. Cancer Res 60: 6744-6749
15. Janes PW, Lackmann M, Church WB, Sanderson GM, Sutherland RL, Daly RJ (1997) Structural determinants of the interaction between the erbB2 receptor and the Src homology 2 domain of Grb7. J Biol Chem 272: 8490-8497
16. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer Statistics 2003. CA Cancer J Clin 53: 5-26
17. Kalil NG, McGuire WP (2002) Chemotherapy for advanced epithelial ovarian carcinoma. Best Pract Res Clin Obstet Gynaecol 16: 553-571
18. Kalli KR, Falowo OI, Bale LK, Zschunke MA, Roche PC, Conover CA (2002) Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. Endocrinology 143: 3259-3267
19. Levenback C, Burke TW, Silva E, Morris M, Gershenson DM, Kavanagh JJ, Wharton JT (1992) Uterine papillary serous carcinoma (USPC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol 46: 317-321
20. Nicklin JL, Copeland LJ (1996) Endometrial papillary serous carcinoma: pattern of spread and treatment. Clin Obstet Gynecol 39: 686-695
21. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937-1947
22. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Cannon MJ, Parham GP (2000) In vitro induction of tumour-specific human lymphocyte antigen class I restricted CD8+ cytotoxic T lymphocytes by ovarian tumour antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Am J Obstet Gynecol 183: 601-609
23. Santin AD, Bellone S, Ravaggi A, Roman JJ, Pecorelli S, Parham GP, Cannon MJ (2002a) Induction of tumour specific CD8+ cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with serous papillary cancer. Brit J Cancer 86: 151-157
24. Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP (2002b) Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res 8: 1271-1279
25. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, Misek DE, Wu R, Zhai Y, Darrah DM, Reed H, Ellenson LH, Giordano TJ, Fearon ER, Hanash SM, Cho KR (2002) Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62: 4722-4729
26. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ (1992) Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathological features. Am J Surg Pathol 16: 600-610
27. Slamon DL, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792
28. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874
29. Steinfeld R, Van Den Berghe H, David G (1996) Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface-associated syndecans and glypican. J Cell Biol 133: 405-416
30. Tusher VG, Tibshirani R, Chu G. (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116-5121
31. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM (2001) Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Aca Sci USA 98: 1176-1181
32. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy Jr J (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99: 1745-1757